Akcje

Kapitalizacja (USD)	664 215 300
Aktywa:	1 233 763 000
Cena:	21.7
Wskaźnik Altman Z-Score:	4.6 Stabilny (niskie ryzyko bankructwa)
Dywidenda:	0
P/E:	-13.1
Ilość akcji w obrocie:	66%
Średni wolumen:	275 877
Ilość akcji	30 609 000

Przychody TTM	277 761 000
Zobowiązania:	98 865 000
Przedział 52 tyg.:	14.57 - 23.987
Piotroski F-Score:	3 Słaby (niska jakość finansowa)
EPS:	-1.7
P/E branży:	31.3
Beta:	1.508
Raport okresowy:	2025-11-05
WWW:	https://www.fulgentgenetics.com

Imie i Nazwisko	Stanowisko	Wynagrodzenie	Rok urodzenia
Mr. Paul Kim	Chief Financial Officer	879 613	1967
Mr. Jian Xie	Chief Operating Officer & President	868 741	1966
Dr. Hanlin Gao D.A.B.M.G., FACMG, M.D., Ph.D.	Chief Scientific Officer & Laboratory Director	720 702	1967
Mr. Ming Hsieh	Chairman & Chief Executive Officer	2 309 167	1956
Ms. Natalie Prescott	General Counsel & Chief Privacy Officer	0	0
Ms. Ellen Tsui	Vice President of Human Resources	0	0
Ms. Doreen Ng	Vice President of Operations & Compliance and GM of Houston Office	0	0
Mr. Brandon Perthuis	Chief Commercial Officer	0	0
Dr. Lawrence M. Weiss M.D.	Chief Medical Officer	0	1957
Mr. Jakub Sram	Vice President of Business Development & Sales	0	0

Symbol ETF	Ilość akcji	Wartość
IWM	512 907	8 811 741
XSPX.L	207 783	270 508 978
XSPU.L	207 783	3 569 709
XS5E.DE	207 783	3 125 994
XS5G.L	207 783	2 705 089
D5BM.DE	207 783	3 125 994
XSXD.L	207 783	3 569 709
DFAT	194 114	3 334 878
IWN	183 916	3 159 673
IBB	120 377	2 068 070
VTWO	106 799	2 123 164
FNDA	105 044	1 814 495
SCHA	92 920	1 608 291
DFAS	83 432	1 433 361
PRFZ	62 691	1 096 465
VHT	61 595	1 224 508
DFAC	61 473	1 056 106
XMWD.L	60 755	1 043 768
XWEH.DE	60 755	914 027
DBXW.DE	60 755	914 027
XBAK.DE	50 634	761 771
XBAK.L	50 634	869 900
AVSC	43 910	767 985
ITOT	35 068	602 460
XHS	34 680	612 746
HTEC	32 697	0
R2SC.L	30 815	408 414
R2US.L	30 815	538 954
ZPRR.DE	30 815	471 962
SVAL	27 391	479 068
SXRG.DE	27 066	406 772
CSUSS.MI	27 066	406 772
CUS1.L	27 066	351 940
CUSS.L	27 066	464 989
IHF	22 318	383 415
SCHB	15 924	277 461
GSSC	14 684	287 512
SBIO	14 552	250 003
JPSE	14 226	244 402
WSML.L	14 095	242 149
IUSN.DE	14 095	211 831
WLDS.L	14 095	183 277
XRS2.DE	13 995	210 548
XRSU.L	13 995	240 435
XRSG.L	13 995	18 219 926
VTWV	13 838	275 099
SMMV	12 981	227 037
AGES.L	12 601	163 857
AGED.L	12 601	216 491
2B77.DE	12 601	189 386
GNOM	10 858	186 540
RSSL	10 601	182 125
EDOC	9 458	161 258
FHLC	8 093	145 835
AVUS	7 703	134 725
WSCR.L	6 742	118 456
DFAU	5 802	99 678
IWV	5 301	91 070
GINN	4 786	93 709
ZPRV.DE	3 806	50 777
USSC.L	3 806	57 985
XSU.TO	3 624	87 517
DCOR	2 266	38 929
DFSU	2 221	38 156
UWM	2 122	36 455
VTHR	1 885	37 473
SPGM	1 859	32 585
URTY	1 756	30 168
OMFS	1 659	29 015
CBUG.DE	1 613	24 235
EWSA.AS	1 613	27 704
FNDB	874	15 185
XUU.TO	623	15 037
AVSU	519	9 077
XGRO.TO	431	10 403
XBAL.TO	198	4 789
XUH.TO	92	1 607
XAW.TO	78	1 875
HDG	25	429
DXUV	24	412
XCNS.TO	16	375
XTR.TO	4	65
USUE.DE	0	0
PZW.TO	0	5 147
RTYS.L	0	34 082
SC0K.DE	0	29 862
USFM.L	0	0

Wiadomości dla Fulgent Genetics, Inc.

Tytuł	Treść	Źródło	Aktualizacja	Link
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc	PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION	globenewswire.com	2025-05-16 12:48:00	Czytaj oryginał (ang.)
Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript	Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript	seekingalpha.com	2025-05-02 16:27:09	Czytaj oryginał (ang.)
Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates	Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.01 per share a year ago.	zacks.com	2025-05-02 13:10:41	Czytaj oryginał (ang.)
Fulgent Reports First Quarter 2025 Financial Results	EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $73.5 million Core Revenue1 grew 16% year-over-year to $73.5 million GAAP loss of $11.5 million, or ($0.37) per share Non-GAAP income of $1.2 million, o.	businesswire.com	2025-05-02 11:00:00	Czytaj oryginał (ang.)
Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025	EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2025 financial results before the market opens on Friday, May 2, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer question.	businesswire.com	2025-04-10 20:05:00	Czytaj oryginał (ang.)
Stock Picks From Seeking Alpha's March 2025 New Analysts	In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT, financials, utilities, materials, and mining—and provided ratings ranging from Strong Sell to Strong Buy. Top picks include C3.ai, Robinhood, Central Puerto, CF Industries, and Kyndryl.	seekingalpha.com	2025-04-04 18:30:59	Czytaj oryginał (ang.)
Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy	CFO bought 1.5 million worth on March 5th, a Price/Book ratio of 0.43x and a Net Current Assets Value (NCAV) of 0.68x that day. Now it's trading at 0.47x Price/Book Value and 0.72x NCAV, showing a significant undervaluation. However, nothing is cheap for no reason; the company is not making money and won't for a while.	seekingalpha.com	2025-03-20 07:46:16	Czytaj oryginał (ang.)
Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript	Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Solomon - IR Ming Hsieh - Chairman and CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - CFO Conference Call Participants David Westenberg - Piper Sandler Lu Li - UBS Andrew Cooper - Raymond James Operator Greetings and welcome to the Fulgent Genetics Q4 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode.	seekingalpha.com	2025-02-28 13:57:31	Czytaj oryginał (ang.)
Fulgent Genetics Revenue Tops Estimates	Laboratory services and therapeutic development specialist Fulgent Genetics (FLGT 0.53%) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday, Feb. 28, the company reported adjusted EPS of $0.04, outstripping expectations of a $0.12 per-share loss.	fool.com	2025-02-28 12:44:00	Czytaj oryginał (ang.)
Fulgent Genetics, Inc. (FLGT) Q4 Earnings and Revenues Beat Estimates	Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to earnings of $0.28 per share a year ago.	zacks.com	2025-02-28 11:10:23	Czytaj oryginał (ang.)
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results	EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Results: Total Revenue of $76.2 million Core Revenue1 grew 14% year-over-year to $76.0 million GAAP loss of $5.9 million, or ($0.19) per share Non-GAAP income.	businesswire.com	2025-02-28 09:00:00	Czytaj oryginał (ang.)
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025	EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Friday, February 28, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the result.	businesswire.com	2025-02-06 18:05:00	Czytaj oryginał (ang.)
Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics	BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--Foundation Medicine to launch two new hereditary germline tests in the United States through a partnership with Fulgent Genetics.	businesswire.com	2025-02-04 18:00:00	Czytaj oryginał (ang.)
Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside	Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside	seekingalpha.com	2024-12-24 03:25:23	Czytaj oryginał (ang.)
Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should Know	The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 31.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.	zacks.com	2024-12-09 12:56:09	Czytaj oryginał (ang.)
All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy	Fulgent Genetics (FLGT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).	zacks.com	2024-11-22 15:00:23	Czytaj oryginał (ang.)
New Strong Buy Stocks for November 22nd	SNEX, PKG, APAM, MNDY and FLGT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2024.	zacks.com	2024-11-22 09:05:16	Czytaj oryginał (ang.)
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript	Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chairman, Chief Executive Officer Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conference Call Participants Li Lu - UBS David Westenberg - Piper Sandler Andrew Cooper - Raymond James Operator Greetings and welcome to the Fulgent Genetics Q3 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode.	seekingalpha.com	2024-11-11 04:07:06	Czytaj oryginał (ang.)
Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates	Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.39 per share a year ago.	zacks.com	2024-11-08 11:15:27	Czytaj oryginał (ang.)
Fulgent Reports Third Quarter 2024 Financial Results	EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Results: Total Revenue of $71.7 million Core Revenue1 grew 9% year-over-year to $71.7 million GAAP loss of $14.6 million, or ($0.48) per share Non-GAAP income of $9.4 million.	businesswire.com	2024-11-08 09:00:00	Czytaj oryginał (ang.)
Fulgent to Participate in Upcoming Conferences	EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 12th at 2:45 PM Pacific Time Piper Sandler 36th Annual Healthcare Conference on Wednesday, Decemb.	businesswire.com	2024-11-05 10:00:00	Czytaj oryginał (ang.)
Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains?	Fulgent Genetics (FLGT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.	zacks.com	2024-11-01 11:10:27	Czytaj oryginał (ang.)
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1	EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has been awarded a five-year contract by the U.S. Department of Veterans Affairs (VA) to provide hereditary cancer, pharmacogenetic and other genetic testing to Veterans. A leader in clinical molecular diagnostic testing, Fulgent has been periodically prov.	businesswire.com	2024-10-31 10:00:00	Czytaj oryginał (ang.)
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024	EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer que.	businesswire.com	2024-10-17 20:05:00	Czytaj oryginał (ang.)
Fulgent Genetics: An NCAV Pick With Profit And Growth Potential	Fulgent Genetics is transitioning from a diagnostic business to a fully integrated healthcare company, with a focus on oncology. Despite past reliance on COVID-19 test revenues, Fulgent's core business has grown significantly, with a strong balance sheet and zero debt. Trading below a conservative estimate of liquidation value, Fulgent presents a rare investment opportunity with potential for future growth and margin expansion as a bonus.	seekingalpha.com	2024-09-25 15:32:42	Czytaj oryginał (ang.)
Fulgent Genetics: Core Growth Re-Acceleration Will Be The Critical Catalyst	Fulgent Genetics' core revenue grew just 3% in H1 2024, with full-year guidance of $280 million implying a step-up to 11% growth in H2 and 7% for FY 2024. Growth in precision diagnostics (+35% in H1 2024) and gross margin expansion (+650 basis points) were the two bright spots in first half results. Headwinds in anatomic pathology and BioPharma services will soften starting H2 2024, paving the way for core growth re-acceleration and operating margin improvements.	seekingalpha.com	2024-09-09 16:05:41	Czytaj oryginał (ang.)
Fulgent Genetics (FLGT) Upgraded to Buy: What Does It Mean for the Stock?	Fulgent Genetics (FLGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.	zacks.com	2024-08-13 17:00:56	Czytaj oryginał (ang.)
How Much Upside is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22%	The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 27.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.	zacks.com	2024-08-13 14:55:49	Czytaj oryginał (ang.)
Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates	Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.08 per share a year ago.	zacks.com	2024-08-02 13:17:25	Czytaj oryginał (ang.)
Fulgent Reports Second Quarter 2024 Financial Results	EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2024. Second Quarter 2024 Results: Total Revenue of $71.0 million Core Revenue1 grew 5% year-over-year to $70.2 million GAAP loss of $8.7 million, or ($0.29) per share Non-GAAP income of $4.7 million, or.	businesswire.com	2024-08-02 11:00:00	Czytaj oryginał (ang.)
Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?	Fulgent Genetics (FLGT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.	zacks.com	2024-07-18 09:41:21	Czytaj oryginał (ang.)
Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing	PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization.	globenewswire.com	2024-06-10 05:00:00	Czytaj oryginał (ang.)
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer	EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, was presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in Chicago, Illinois. Of eleven head and neck squamous cell carcinoma (HNSCC).	businesswire.com	2024-06-03 12:00:00	Czytaj oryginał (ang.)

Sektor:	Zdrowie
Branża:	Medical - Diagnostics & Research
Zatrudnienie:	1 184
Giełda:	NASDAQ Global Market
Ilość akcji w obrocie:	66.0379
Ilość akcji:	Brak danych
Debiut giełdowy:	2016-09-29
WWW:	https://www.fulgentgenetics.com
CEO:	Mr. Ming Hsieh
Adres:	4978 Santa Anita Avenue
Siedziba:	91780 Temple City
ISIN:	US3596641098

Notowania:

Opis firmy:

Informacje o spółce:

Wskaźniki finansowe

Wskaźniki finansowe

Zarząd

Lista ETF z ekspozycją na akcje Fulgent Genetics, Inc.

Wiadomości dla Fulgent Genetics, Inc.